In almost two decades since the initial reports of long-term disease free survival after chemotherapy for the diffuse aggressive lymphomas (Levitt et al., 1972; De Vita et al., 1975) a variety of newer, more complex and more toxic regimens have been described which are said to improve remission rates and survival (Schein et al., 1976; Laurence et al., 1982; Fisher et al., 1983; Skarin et al., 1983; Klimo & Connors, 1985) . The evaluation of such claims is however made difficult by the heterogeneity of the patient populations studied and lack of a well recognised set of prognostic factors. The recent introduction of yet more intensive consolidation with autologous bone marrow support (Applebaum et al., 1978; Philip et al., 1985; Armitage et al., 1986; Takvorian et al., 1987; Goldstone et al., 1988) has made the identification of such factors more pressing still, to allow some judgement of the likelihood of recurrence after conventional treatment and hence the rationale for ablative proce- dures.
In the search for prognostic factors it has been suggested that serum ,-2 microglobulin may be a useful indicator of disease extent and activity in lymphomas, although the results have not been uniform. As the light chain common to the major histocompatability (HLA) antigens A, B and C (Cresswell et al., 1974) it is shed into the circulation at a rate determined by lymphocyte activation and proliferation (Azocar et al., 1982) . Studies in multiple myeloma have confirmed its usefulness as an independent prognostic marker (Bataille et al., 1983 ) whilst in non-Hodgkin's lymphoma levels have been correlated with extent of disease, response to chemotherapy and survival (Spati et al., 1978; Child et al., 1980; Hagberg et al., 1983; Legros et al., 1987) . Recently it has been suggested that a serologic staging system based upon P-2 microglobulin and lactate dehydrogenase (LDH) levels may identify sub-groups with differing disease-free and overall survival more distinctly than conventional staging by the Ann Arbor criteria (Swan et al., 1989) . (Carbone et al., 1971 (Table  I) . Table II ). One patient received only palliative treatment and three received initial radiotherapy followed by a combination of adriamycin, vincristine, prednisolone and L-asparaginase. Re-evaluation was carried out at the end of chemotherapy by repeating the tests which had previously been abnormal. A complete response (CR) was defined as the disappearance of all clinical, laboratory and radiographic evidence of lymphoma. Responding patients with minimal residual radiographic abnormalities were classified as showing good partial response (GPR). Lesser objective responses were classified as poor partial response (PPR). Duration of remission for patients reaching clinical remission (CR or GPR) was measured from the date of determination of response.
Levels of P-2 microglobulin in different groups were compared using the Mann-Whitney U test, and the proportions of patients with elevated levels compared by the x2 test. Univariate analysis of prognostic factors was carried out both by the log-rank test with groups separated by the normal range for continuous variables and by use of a (Cox, 1972) .
Results
The mean level of P-2 microglobulin at presentation was 3.85 mg 1`(range 0.51 to 25.24 mg -', with a standard deviation of 3.16). One hundred and twenty patients (46%) had levels greater than the upper limit of normal (3.0 mg 1-l).
Fourteen patients with elevated levels of P-2 microglobulin had evidence of significant renal impairment at presentation with serum creatinine greater than 150 jmol I'. Since reduced renal clearance results in falsely high levels (Schardjin & Van Eps, 1987) The outcome of chemotherapy correlated with initial 13-2 microglobulin: 70% of those with normal levels reached clinical remission, as compared to only 37% of those with elevated levels (P <0.001) (Figure 3) .
With an overall median follow-up time of 6 years, for the 138 patients entering clinical remission the disease-free interval was significantly longer for those who had an initially normal 13-2 microglobulin. The median duration of remission in the normal group was over 6 years, compared to 19 months for those with elevated levels (P <0.001). There was a marked difference between the two groups in number of long term survivors free from recurrence: The group with normal levels had 70% of patients remaining free from disease at 6 years compared to only 35% of those with high levels, (Figure 4 ). This distinction arose principally from the difference in rates of recurrence (24% vs 56%) rather than deaths in remission from other causes.
Overall survival ( Figure 5) two decades ago (Levitt et al., 1972; De Vita et al., 1975) . The use of anthracycline-based four-drug chemotherapy regimens such as CHOP (cyclophosphamide, doxorubicin, vincristine and prednisolone) has resulted in long-term diseasefree survival for a substantial minority of patients (McKelvey et al., 1975; Coltman et al., 1986) , whilst more complex and toxic regimens using larger numbers of drugs have been apparently more effective when judged against historical controls (Schein et al., 1976; Laurence et al., 1982; Fisher et al., 1983; Skarin et al., 1983; Klimo & Connors, 1985) . The results with such regimens used at different institutions have however rarely matched those of their originators (Schneider et al., 1990; Weick et al., 1991) and phase III trials of direct comparison have failed to demonstrate a clear advantage for the more complex treatments (O'Connell et al., 1984; Gordon et al., 1989) . Several confounding factors make these results difficult to interpret: The treatment given may differ from that planned, and reductions in dose intensity, particularly frequent for older patients receiving complex regimens, may compromise cure rates . The extent of experience at a particular centre may also influence outcome (Browne et al., 1986) , but probably the greatest variability lies in the patient populations studied. The lack of a comprehensive set of prognostic factors which can be applied objectively for stratification makes even the results of randomised trials suspect, whilst historical controls are less reliable still.
The increasing application of intensive consolidation of remission by ablative treatment with autologous stem-cell support (Applebaum et al., 1978; Philip et al., 1985; Armitage et al., 1986; Takvorian et al., 1987; Goldstone et al., 1988) has heightened the importance of identifying those patients for whom the risk of recurrence is high. Whereas previously all patients reaching remission would be observed without further treatment, there are now therapeutic as well as prognostic implications in the analysis. For high-risk patients these treatments may offer a sign,ificant improvement in survival, whilst for those already likely to be cured aggressive regimens represent only the chance of further toxicity and morbidity. Once again prognostic factors capable of discriminating such groups still require definition themselves.
Previous studies in non-Hodgkin's lymphoma have shown a correlation between stage of disease and P-2 microglobulin level (Spati et al., 1978; Child et al., 1980; Hagberg et al., 1983; Legros et al., 1987) (Moller et al., 1986) , and that changes in HLA complex proteins which impair light and heavy chain association result in enhanced release of P-2 microglobulin (Ferrier et al., 1985; Rein et al., 1987) .
The considerably lower risk of recurrence and longer duration of remission in patients with normal P-2 microglobulin levels also accord with the results of previous smaller studies (Hagberg et al., 1983) . Once again it may be postulated that this relates to the effectiveness of host immune surveillance. The overall survival differences are also in agreement with previous reports (Legros et al., 1987; Han et al., 1989) . The finding that 13-2 microglobulin remained an independent prognostic factor in multivariate analysis provides further confirmation of its potential in this group of diseases, with the possibility in future for derivation of a serologic staging system to replace the increasingly outmoded Ann Arbor classification. The finding that albumin was of equivalent but independent prognostic significance in these patients reflects its position as an indirect measure of their general condition at presentation, which might be expected to parallel performance status, had this been available. The implication from this analysis is that the combination of patient-related albumin and disease-related ,-2 microglobulin is the most useful set of factors to analyse. Other studies may find different factors of importance within these two categories, and in this context the results of the international collaborative investigation of prognostic factors already underway will be eagerly awaited.
In conclusion, P-2 microglobulin is an independent prognostic factor for response to treatment, duration of remission and survival in patients with diffuse aggressive non-Hodgkin's lymphomas. It remains significant in multivariate analyses and in the future prospective studies should be performed to validate these observations. Whilst it is inevitable that prognostic factors are of relevance in inverse proportion to the efficacy of treatment, it may be that the derivation of a reproducible prognostic index will in turn help the identification of more effective regimens.
